Skip to content

Contact +44 (0) 20 7060 7474 email us

Clinical Trials

Neurostimulation Devices Clinical Trial Analysis

 

Publication Date July 2009
Publisher Global Markets Direct
Product Type
Pages 57
ISBN Number not applicable
Product Code GMD02918

Price

£655.00
approximately: $1,003 | €730

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

Global Markets Direct's "Neurostimulation Devices Clinical Trials Analysis" is an essential source of data and information pertaining to product clinical trials being carried out by Neurostimulation Devices manufacturers, globally. The report provides exhaustive information on each clinical investigation study with coverage detailed coverage on the pipeline products these trials are being carried out for.

Scope

  • The report provides analysis and review of the key clinical trials being carried out globally and across key Neurostimulation Devices market categories - Deep Brain Stimulators,Spinal Cord Stimulators,Vagus Nerve Stimulators
  • The report covers information on each product being clinically tested with detailed coverage on the pipeline product profile, the indication it's being investigated for etc.
  • The report provides an in-depth analysis of the clinical trials with information on trial phase, trial 0status, trial acronym, purpose, inclusion and exclusion criteria, description, design, intervention, investigator information, primary and secondary end-points and trial results
  • The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Global Markets Direct's team of industry experts.

Reasons to Buy

  • Effectively plan your Mergers and Acquisitions and partnership strategies by identifying companies with the most promising pipeline.
  • Stay ahead of the information curve in the fast changing Neurostimulation Devices market.
  • Plan in-licensing and out-licensing opportunities through review of pipeline products and technologies.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Proactively plan and execute your competitive strategies by identifying clinical trials status of the leading competitive products in pipeline.
  • Stay ahead of competition by understanding the changing competitive landscape in specific geographies.

Contents

  • 1 List of Tables
  • 1.2 List of Figures
  • 2 Neurostimulation Devices Clinical Trials
    • 2.1 Neurostimulation Devices Clinical Trial By Equipment Type
    • 2.2 Neurostimulation Devices Clinical Trials By Trial Phase and Trial Status
    • 2.3 Neurostimulation Devices Pipeline Products By Development Stage
    • 2.4 Neurostimulation Devices Pipeline Products By Therapy Area
    • 2.5 Neurostimulation Devices Pipeline Products By News Summary
    • 2.6 Neurostimulation Devices CardioFit system
      • 2.6.1 CardioFiT for Heart Failure - Safety and Efficacy Study Protocol
    • 2.7 Neurostimulation Devices Reclaim for Depression
      • 2.7.1 Deep Brain Stimulation of the Internal Capsule for Severe and Medically Refractory Major Depression
      • 2.7.2 Prospective,Randomised, Double-Blind, Multicenter Study To Assess The Efficacy And Safety Of Bilateral Globus Pallidus Internus -In Patients With Medically Refractory Primary Cervical Dystonia
      • 2.7.3 Randomisierte, Doppelblinde Langzeitstudie Zur Klinischen Wirksamkeit Der Bilateralen Globus Pallidus Internus-Stimulation Bei Idiopathischer Generalisierter Oder Segmentaler Dystonie
      • 2.7.4 Deep Brain Stimulation For Treatment-Refractory Major Depression
      • 2.7.5 Investigation Of Efficacy And Safety Of Deep Brain Stimulation Of The Cingulate Cortex In Patients With Treatment Resistant Major Depression
      • 2.7.6 Reclaim Deep Brain Stimulation Clinical Study For Treatment-Resistant Depression
    • 2.8 Neurostimulation Devices Andara Oscillating Field Stimulator system
      • 2.8.1 Andara Oscillating Field Stimulator system - Clinical Study Results
      • 2.8.2 Andara Oscillating Field Stimulator In Phase I Clinical Trial
    • 2.9 Neurostimulation Devices Renova-DT Cortical Stimulation System
      • 2.9.1 Feasibility Study of the Safety and Effectiveness of Cortical Stimulation for Subjects With Major Depressive Disorder
  • 3 Recent Developments
    • 3.1 Product News
      • 3.1.1 Jun 08, 2009: St. Jude Medical Announces Completion Of Patient Implants In US Pivotal Study Of DBS For Parkinson's Disease
      • 3.1.2 May 21, 2009: Medtronic Announces Approval Of Activa RC And Activa PC Devices For Patients With Movement Disorders In US
      • 3.1.3 May 21, 2009: St. Jude Releases Results Of The Libra DBS Canadian Study
      • 3.1.4 Feb 24, 2009: St. Jude Medical Announces Australian TGA And Reimbursement Approval For The Eon Mini Neurostimulator
      • 3.1.5 Feb 19, 2009: Reclaim Deep Brain Stimulation (DBS) Therapy Of Medtronic Receives FDA HDE Approval For A Psychiatric Indication
      • 3.1.6 Feb 17, 2009: Mobilis Healthcare Offers InterX Neurostimulation Technology For Pain Management
      • 3.1.7 Feb 17, 2009: Mobilis Healthcare Offers New InterX Neurostimulation Technology For Pain Management
      • 3.1.8 Feb 11, 2009: Surgeons At UT Southwestern Medical Center Performs First Local Implant In Deep Brain Stimulation Study For Depression
      • 3.1.9 Jan 26, 2009: Uroplasty Announces Patient Enrollment In Urgent PC SUmiT Clinical Trial Completed Ahead Of Schedule
      • 3.1.10 Jan 07, 2009: Cyberonics Presents Business Updates On Depression Clinical Trial
      • 3.1.11 Dec 08, 2008: Data From Pivotal Study Show Medtronic Deep Brain Stimulation Therapy Reduced Seizure Rate In Patients With Severe Epilepsy
      • 3.1.12 Nov 10, 2008: Boston Scientific Announces Start Of Clinical Trial Assessing Precision Spinal Cord Stimulator For Treatment Of Migraine Headaches
      • 3.1.13 Nov 06, 2008: Newly Published Data From Long-Term Study Show Neurostimulation Provides Sustained Leg Pain Relief, Improved Quality Of Life And Functional Capacity
      • 3.1.14 Oct 30, 2008: Texcel Introduces Innovative Programmable, Implantable Stimulation System For R&D
      • 3.1.15 Oct 22, 2008: Pre-Market Approval Application For FDA Approval Of InterStim Therapy For Fecal Incontinence Submitted By Medtronic
      • 3.1.16 Oct 14, 2008: Northstar Neuroscience Receives FDA Approval For A Clinical Study Of Its Cortical Stimulation System For The Treatment Of Major Depressive Disorder
      • 3.1.17 Oct 08, 2008: FDA Clears Neuronetics's NeuroStar TMS Therapy For The Treatment Of Depression
      • 3.1.18 Oct 03, 2008: Uroplasty Enrolls First Patients In Urgent PC Clinical Trial
      • 3.1.19 Oct 01, 2008: Cyberonics Provides Update On Depression Indication
      • 3.1.20 Sep 17, 2008: Former US Army Parachutist Becomes First Person Implanted With The World's Smallest Neurostimulator To Treat Chronic Pain
      • 3.1.21 Aug 21, 2008: AorTech Issued Patent For Biostable Polyurethanes
      • 3.1.22 Jul 30, 2008: Bioness Announces NESS H200 Systems To Be Available At 88 HealthSouth Hospitals Nationwide
      • 3.1.23 Sep 01, 2007: Innovative Neurotronics Earned The da Vinci Award For WalkAide System
      • 3.1.24 Aug 29, 2007: Nerve Stimulation Plus Ultrasound Improves Safety In Regional Anesthesia
      • 3.1.25 Jun 19, 2007: One Of First Patients To Be Implanted With Cyberkinetics' Andara OFS System For Spinal Cord Injury To Meet With Members Of Congress
      • 3.1.26 Jun 15, 2007: Neurostar Tms Therapy Produced Significant Improvements In Depression Symptoms In Recently-Published Randomized, Controlled Trial
      • 3.1.27 Jun 15, 2007: Neurostar TMS Therapy Produced Significant Improvements In Depression Symptoms In Recently-Published Randomized, Controlled Trial
      • 3.1.28 Feb 28, 2007: St. Jude Medical Announces Spinal Cord Stimulation Pilot Study For Chronic Angina
      • 3.1.29 May 02, 2006: Hanger Orthopedic Group Announces The Launch Of WalkAide System
    • 3.2 Product Approvals
      • 3.2.1 May 21, 2009: Medtronic Announces Approval Of Activa RC And Activa PC Devices For Patients With Movement Disorders In US
      • 3.2.2 Feb 24, 2009: St. Jude Medical Announces Australian TGA And Reimbursement Approval For The Eon Mini Neurostimulator
      • 3.2.3 Feb 19, 2009: Reclaim Deep Brain Stimulation (DBS) Therapy Of Medtronic Receives FDA HDE Approval For A Psychiatric Indication
      • 3.2.4 Oct 08, 2008: FDA Clears Neuronetics's NeuroStar TMS Therapy For The Treatment Of Depression
    • 3.3 Clinical Trials
      • 3.3.1 Jun 08, 2009: St. Jude Medical Announces Completion Of Patient Implants In US Pivotal Study Of DBS For Parkinson's Disease
      • 3.3.2 May 21, 2009: St. Jude Releases Results Of The Libra DBS Canadian Study
      • 3.3.3 Feb 11, 2009: Surgeons At UT Southwestern Medical Center Performs First Local Implant In Deep Brain Stimulation Study For Depression
      • 3.3.4 Jan 26, 2009: Uroplasty Announces Patient Enrollment In Urgent PC SUmiT Clinical Trial Completed Ahead Of Schedule
      • 3.3.5 Dec 08, 2008: Data From Pivotal Study Show Medtronic Deep Brain Stimulation Therapy Reduced Seizure Rate In Patients With Severe Epilepsy
      • 3.3.6 Nov 10, 2008: Boston Scientific Announces Start Of Clinical Trial Assessing Precision Spinal Cord Stimulator For Treatment Of Migraine Headaches
      • 3.3.7 Nov 06, 2008: Newly Published Data From Long-Term Study Show Neurostimulation Provides Sustained Leg Pain Relief, Improved Quality Of Life And Functional Capacity
      • 3.3.8 Oct 14, 2008: Northstar Neuroscience Receives FDA Approval For A Clinical Study Of Its Cortical Stimulation System For The Treatment Of Major Depressive Disorder
      • 3.3.9 Oct 03, 2008: Uroplasty Enrolls First Patients In Urgent PC Clinical Trial
  • 4 Appendix
    • 4.1 Methodology
      • 4.1.1 Coverage
      • 4.1.2 Secondary Research
      • 4.1.3 Primary Research
      • 4.1.4 Expert Panel Validation
    • 4.2 Contact Us
    • 4.3 About Global Markets Direct
    • 4.4 Disclaimer
  • 1 List of Tables
    • Table 1: Neurostimulation Devices Clinical Trial By Equipment Type
    • Table 2: Neurostimulation Devices Clinical Trials By Trial Phase and Trial Status
    • Table 3: Neurostimulation Devices Pipeline Products By Development Stage
    • Table 4: Neurostimulation Devices Pipeline Products By Therapy Area
    • Table 5: Neurostimulation Devices Pipeline Products By News Summary
    • Table 6: CardioFit system - CardioFiT for Heart Failure - Safety and Efficacy Study Protocol
    • Table 7: Reclaim for Depression - Deep Brain Stimulation of the Internal Capsule for Severe and Medically Refractory Major Depression
    • Table 8: Reclaim for Depression - Prospective,Randomised, Double-Blind, Multicenter Study To Assess The Efficacy And Safety Of Bilateral Globus Pallidus Internus -In Patients With Medically Refractory Primary Cervical Dystonia
    • Table 9: Reclaim for Depression - Randomisierte, Doppelblinde Langzeitstudie Zur Klinischen Wirksamkeit Der Bilateralen Globus Pallidus Internus-Stimulation Bei Idiopathischer Generalisierter Oder Segmentaler Dystonie
    • Table 10: Reclaim for Depression - Deep Brain Stimulation For Treatment-Refractory Major Depression
    • Table 11: Reclaim for Depression - Investigation Of Efficacy And Safety Of Deep Brain Stimulation Of The Cingulate Cortex In Patients With Treatment Resistant Major Depression
    • Table 12: Reclaim for Depression - Reclaim Deep Brain Stimulation Clinical Study For Treatment-Resistant Depression
    • Table 13: Andara Oscillating Field Stimulator system - Andara Oscillating Field Stimulator system - Clinical Study Results
    • Table 14: Andara Oscillating Field Stimulator system - Andara Oscillating Field Stimulator In Phase I Clinical Trial
    • Table 15: Renova-DT Cortical Stimulation System - Feasibility Study of the Safety and Effectiveness of Cortical Stimulation for Subjects With Major Depressive Disorder
  • 1.2 List of Figures
    • Figure 1: Global Markets Direct Methodology